ArticleScientific reports2025
Characterization of neutralizing versus binding antibody and T cell responses to varicella-zoster virus in the elderly.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Screening and identification of B-cell epitopes on the gH protein of varicella-zoster virus.Archives of microbiology · 2026Article
- Review
- Varicella-Zoster Virus and the Eye: Clinical Spectrum, Management, and Vaccination.Pathogens (Basel, Switzerland) · 2026Review
- Predictors of Severe Herpes Zoster: Contributions of Immunosenescence, Metabolic Risk, and Lifestyle Behaviors.Diseases (Basel, Switzerland) · 2026Article
- Review
- The gut and circulating virome: emerging players in aging and longevity.Frontiers in aging · 2025Review
- A novel adjuvant system BK-02 with CpG2006 and MF59 enhances the immunogenicity of a herpes zoster subunit vaccine.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Age-related immune changes increase the risk of herpes zoster (HZ) caused by varicella-zoster virus (VZV) reactivation. Understanding immune responses to VZV is crucial for reducing the burden of HZ in aging populations. Due to the limited availability of data regarding the VZV immune profiles of elderly individuals, particularly in developing countries, more comprehensive immunological investigations are warranted. A total of 213 participants aged ≥ 60 years were included in this study. VZV-neutralizing antibodies (NAb) and glycoprotein-binding antibodies (BAb) were quantified. Furthermore, VZV-specific T cell subsets and their functionality were evaluated using flow cytometry. Elderly individuals demonstrated a high VZV seropositivity rate of 98.6%, exceeding that of the younger adults. Interestingly, VZV-BAb increased, whereas the proportion of NAb decreased with age, with a significantly lower proportion in the elderly aged ≥ 70 years. The elderly showed decreased naïve T cells and accumulated VZV-specific aged T cells; central memory and effector memory CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.